Use of a post-sleep questionnaire-interactive voice response system (PSQ-IVRS) to evaluate the subjective sleep effects of ramelteon in adults with chronic insomnia

S Wang-Weigand, M Watissée, T Roth - Sleep medicine, 2011 - Elsevier
OBJECTIVE: Ramelteon is an MT1/MT2 melatonin receptor agonist approved in the US and
Japan for the treatment of sleep-onset insomnia. This study evaluated the effects of …
被引用次数：18 相关文章

Use of a post-sleep questionnaire-interactive voice response system (PSQ-IVRS) to evaluate the subjective sleep effects of ramelteon in adults with chronic insomnia

S Wang-Weigand, M Watissée, T Roth - Sleep Medicine, 2011 - infona.pl
Ramelteon is an MT 1/MT 2 melatonin receptor agonist approved in the US and Japan for
the treatment of sleep-onset insomnia. This study evaluated the effects of ramelteon 8mg on …

Use of a post-sleep questionnaire-interactive voice response system (PSQ-IVRS) to evaluate the subjective sleep effects of ramelteon in adults with chronic insomnia.

S Wang-Weigand, M Watissée, T Roth - Sleep Medicine, 2011 - europepmc.org
Objective Ramelteon is an MT (1)/MT (2) melatonin receptor agonist approved in the US and
Japan for the treatment of sleep-onset insomnia. This study evaluated the effects of …

Use of a post-sleep questionnaire-interactive voice response system (PSQ-IVRS) to evaluate the subjective sleep effects of ramelteon in adults with chronic insomnia

S Wang-Weigand, M Watissée, T Roth - 2011 - pubmed.ncbi.nlm.nih.gov
Objective Ramelteon is an MT (1)/MT (2) melatonin receptor agonist approved in the US and
Japan for the treatment of sleep-onset insomnia. This study evaluated the effects of …